Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice

This study has been completed.
Information provided by:
Novo Nordisk A/S Identifier:
First received: December 21, 2011
Last updated: April 11, 2012
Last verified: April 2012
This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.

Condition Intervention
Diabetes Mellitus, Type 2
Drug: repaglinide

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoNorm® in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • HbA1c (glycosylated haemoglobin) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Fasting Plasma Glucose (FPG) [ Designated as safety issue: No ]
  • Postprandial glucose values [ Designated as safety issue: No ]
  • Incidence of hypoglycaemia [ Designated as safety issue: No ]
  • Adverse drug reactions (ADR) [ Designated as safety issue: No ]

Enrollment: 30554
Study Start Date: August 2004
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Repaglinide Drug: repaglinide
Prescription according to the product labelling at the physicians' discretion


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with type 2 diabetes, newly diagnosed or not adequately controlled on their current therapy, who are treated repaglinide by their physicians in accordance with the approved labeling

Inclusion Criteria:

  • Type 2 diabetes
  • Newly diagnosed or not adequately controlled with current therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01498900

China, Beijing
Beijing, Beijing, China, 100004
Amman, Iraq, 11844
Amman, Jordan, 11844
Amman, Lebanon, 11844
Casablanca, Morocco, 20000
Istanbul, Turkey, 34335
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Senior Project Manager for OADs Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S Identifier: NCT01498900     History of Changes
Other Study ID Numbers: AGEE-1875 
Study First Received: December 21, 2011
Last Updated: April 11, 2012
Health Authority: China: Food and Drug Administration
Iraq: Ministry of Health
Jordan: Ministry of Health
Lebanon: Ministry of Public Health
Morocco: Ministry of Health
Turkey: Ministry of Health

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on October 25, 2016